Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884855 | 0.81 | MAPT (0.40) | RAD52GAAKDM4EMAPTTHRB | |
| SCHEMBL4261820 | 0.81 | MAPT (0.40) | RAD52GAAKDM4EMAPTTHRB | |
| SCHEMBL3065769 | 0.69 | GFER (0.52) | GAAKDM4EMAPTALDH1A1TSHR | |
| SCHEMBL6220147 | 0.67 | RAD52 (0.50) | RAD52GAAKDM4EMAPTTHRB | |
| SCHEMBL17264102 | 0.66 | GAA (0.61) | RAD52GAAKDM4EMAPTTHRB | |
| SCHEMBL6151434 | 0.66 | GAA (0.77) | RAD52GAAKDM4EMAPTTHRB | |
| SCHEMBL15358759 | 0.66 | GAA (0.77) | RAD52GAAKDM4EMAPTTHRB | |
| SCHEMBL22652016 | 0.66 | GAA (0.60) | RAD52GAAKDM4EMAPTALDH1A1 | |
| SCHEMBL5390127 | 0.66 | GAA (0.53) | RAD52GAAKDM4EMAPTTHRB | |
| SCHEMBL14938616 | 0.66 | GAA (0.53) | RAD52GAAKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586609-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7838547-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | RAD52 4390/4885GAA 688/4885KDM4E 1496/4885 |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | RAD52 4390/4885GAA 688/4885KDM4E 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.